Literature DB >> 20043716

Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas.

Wolfgang K Pfisterer1, Ronald A Nieman, Adrienne C Scheck, Stephen W Coons, Robert F Spetzler, Mark C Preul.   

Abstract

OBJECT: The goal in this study was to determine if proton ((1)H) MR spectroscopy can differentiate meningioma grade and is associated with interpretations of biological behavior; the study was performed using ex vivo high-resolution spectra indicating metabolic characteristics.
METHODS: Sixty-eight resected tissue samples of meningiomas were examined using ex vivo (1)H MR spectroscopy. Of these meningiomas, 46 were WHO Grade I, 14 were WHO Grade II, and 8 were WHO Grade III. Fifty-nine were primary meningiomas and 9 were recurrences. Invasion of adjacent tissue (dura mater, bone, venous sinus, brain) was found in 32 cases. Thirty-nine meningiomas did not rapidly recur (as defined by expansion on MR imaging within a 5-year follow-up period), whereas rapid recurrence was confirmed in 24 meningiomas, and follow-up status was unknown in 5 cases.
RESULTS: The absolute concentrations of total alanine and creatine were decreased in high-grade compared with low-grade meningiomas, as was the ratio of glycine to alanine (all p < 0.05). Additionally, alanine and the glycine/alanine ratio distinguished between primary and recurrent meningiomas (all p < 0.05). Finally, the absolute concentrations of alanine and creatine, and the glycine/alanine and choline/glutamate ratios were associated with rapid recurrence (p < 0.05).
CONCLUSIONS: These data indicate that meningioma tissue can be characterized by metabolic parameters that are not typically identified by histopathological analysis alone. Creatine, glycine, and alanine may be used as markers of meningioma grade, recurrence, and the likelihood of rapid recurrence. These data validate a previous study of a separate group of Grade I meningiomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043716     DOI: 10.3171/2009.11.FOCUS09216

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  7 in total

1.  Predicting Consistency of Meningioma by Magnetic Resonance Imaging.

Authors:  Kyle A Smith; John D Leever; Roukoz B Chamoun
Journal:  J Neurol Surg B Skull Base       Date:  2015-01-21

2.  Use of preoperative magnetic resonance imaging T1 and T2 sequences to determine intraoperative meningioma consistency.

Authors:  Jason M Hoover; Jonathan M Morris; Fredric B Meyer
Journal:  Surg Neurol Int       Date:  2011-10-12

Review 3.  Evaluation of Cancer Metabolomics Using ex vivo High Resolution Magic Angle Spinning (HRMAS) Magnetic Resonance Spectroscopy (MRS).

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Metabolites       Date:  2016-03-22

4.  Magnetic resonance spectroscopy for the study of cns malignancies.

Authors:  Victor Ruiz-Rodado; Jeffery R Brender; Murali K Cherukuri; Mark R Gilbert; Mioara Larion
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2020-12-02       Impact factor: 9.795

Review 5.  Use of advanced neuroimaging and artificial intelligence in meningiomas.

Authors:  Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

Review 6.  Metabolomics-A Promising Approach to Pituitary Adenomas.

Authors:  Oana Pînzariu; Bogdan Georgescu; Carmen E Georgescu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-17       Impact factor: 5.555

Review 7.  Meningioma: A Review of Clinicopathological and Molecular Aspects.

Authors:  Kristin Huntoon; Angus Martin Shaw Toland; Sonika Dahiya
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.